Declining rates of cervical intraepithelial neoplasia in British Columbia, Canada: An ecological analysis on the effects of the school‐based human papillomavirus vaccination program

Abstract

Since 2008, girls in British Columbia (BC), Canada, have been offered HPV vaccination through a school‐based, publicly funded immunization program. The oldest birth cohort eligible for the vaccination program was born in 1994 and uptake is on average 63%. To evaluate the impact of the HPV vaccine in BC, ecological trends in cervical intraepithelial neoplasia (CIN) rates were assessed in young women before and after the implementation of the HPV vaccination program. Information on all Pap smears and histopathological abnormalities, in calendar years 2004‐2017 in women 16‐28 years of age in BC were obtained from the population‐based BC Cancer Cervix Screening Program database. Rates of CIN 2 and 3 were calculated as the number of cases divided by the number of cytology specimens for that period. Rate ratios (RR) were calculated by negative binomial piecewise regression. Age‐centered incidence rates of CIN 2 and 3 in BC declined significantly among women 16‐23 years of age after HPV vaccine introduction compared to before vaccine introduction. The overall reduction postvaccination for CIN2 and 3 in women 16‐23 years was respectively 62% (95% CI 54‐68%) and 65% (95% CI 58‐71%). Age‐specific rates for CIN2 significantly declined for those 18‐22 years of age and for those 19, 20 and 23 years of age for CIN3. Among women 24‐28 years of age no decline in CIN2 and 3 rate over time was observed. The observed reduction in CIN 2 and 3 rates since the introduction of the school‐based HPV vaccine program might illustrate the population impact of the BC provincial school‐based HPV vaccination program.

Canadian Guideline on the Management of a Positive Human Papillomavirus Test and Guidance for Specific Populations

“…Donker et al from British Columbia recently evaluated the effect of vaccination on CIN2+ lesions. They demonstrated a 62% (95% CI 54–68%) and 65% (58–71) reduction in CIN2 and CIN3, respectively, in the vaccinated population [ 131 ]. The UK has noted similar reductions of 97% (96–98%) for CIN3 and 87% (72–94%) for cervical cancer in vaccinated women [ 132 ].…”